Hirotaka Matsui obtained his MD and PhD degrees from Hamamatsu University School of Medicine in 1995 and 2001, respectively. After training as a hematologist for 6 years, he underwent post-doctoral training with Prof. Toshiya Inaba at the Research Institute for Radiation Biology and Medicine in Hiroshima University, where he identified responsible genes of monosomy 7-related myeloid neoplasms (SAMD9, SAMD9L and HEPACAM2). After spending for 14 years in Hiroshima University, he joined the Kumamoto University as a principal investigator at the department of Molecular Laboratory Medicine and performed research on the roles of DDX41 mutations in myeloid neoplasms. He characterized that DDX41 coordinates RNA splicing and transcriptional elongation, thus preventing the accumulation of DNA replication stress in hematopoietic cells. He is currently the Chief of the Department of Laboratory Medicine in the National Cancer Center Hospital in Japan. He is board-certified in hematology and laboratory medicine in Japan.
Shinichi Masuda is a certified drug therapy specialist, and is a clinical pharmacist at the National Cancer Center Hospital East, Japan. He is a member of the hematology and cancer department, and is part of the medical team specializing in cancer genomes, working as a coordinator. During his Master of Science, he was the first student in the exchange program between Khon Kean University and Kyoritsu College of Pharmacy to obtain a full scholarship due to his outstanding performance. He also completed a clinical internship abroad in the United States. He was a clinical pharmacist at Toho University Medical Center Ohashi Hospital, Tokyo, Japan for 13 years. He won the first prize in the oncology course of the Tokyo Metropolitan Society of Pharmacists within the Tokyo Health System in 2014. He is certified by the Council of Specialized Pharmacists in Drug Therapy and is an active member of the Japanese Society of Pharmaceutical Oncology, as well as a member of an international committee. He is responsible for the pharmaceutical and therapeutic committee, in particular, for biosimilars and generic medicines. He is a tutor of the Japanese Oncology Program and a member of the 2020 Japanese Medical Exchange Program.
